890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Duloxetine Neoplasm	Yan Yang, MD, Ph.D	P2	CC (46)
hlx208 Neoplasm	Shanghai Henlius Biotech	P2	CC (46)
jyp0015 Neoplasm	Guangzhou JOYO Pharma Co., Ltd	P2	CC (46)
Oric-114 Neoplasm	ORIC Pharmaceuticals	P1/2	CC (46)
Pentapeptide-1 Neoplasm	Second Affiliated Hospital of Soochow University	P2	CC (46)
Precemtabart Tocentecan Neoplasm	EMD Serono Research & Development Institute, Inc.	P1/2	CC (46)
prl3-zumab Neoplasm	Intra-IMMUSG Pte Ltd	P2	CC (46)
Rec-4881 Neoplasm	Recursion Pharmaceuticals Inc.	P2	CC (46)
Retifanlimab Neoplasm	Incyte Corporation	P1/2	CC (46)
Ris-Rez Neoplasm	GlaxoSmithKline	P1/2	CC (46)
Sargramostim Neoplasm	Partner Therapeutics, Inc.	P2	CC (46)
Sitravatinib Neoplasm	Haider Mahdi	P2	CC (46)
Suplexa Neoplasm	Alloplex Biotherapeutics Inc	P1	CC (46)
Tilsotolimod Neoplasm	Idera Pharmaceuticals, Inc.	P2	CC (46)
TL118 Neoplasm	Teligene US	P2	CC (46)
Vebreltinib Neoplasm	Tianjin Medical University Second Hospital	P2	CC (46)
ad1208 Neoplasm	Avelos Therapeutics Inc.	P1/2	CC (45)
Amxt1501 Neoplasm	Aminex Therapeutics, Inc.	P1/2	CC (45)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Neoplasm	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CC (45)
bs006 Neoplasm	Binhui Biopharmaceutical Co., Ltd.	P1/2	CC (45)
Camonsertib Neoplasm	Memorial Sloan Kettering Cancer Center	P2	CC (45)
Carbon Nanoparticle-Loaded Iron Neoplasm	Sichuan Enray Pharmaceutical Sciences Company	P1/2	CC (45)
Decitabine Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1/2	CC (45)
IM19 CAR-T cells Neoplasm	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (45)
jk08 Neoplasm	Salubris Biotherapeutics Inc	P1/2	CC (45)
lb1410 Neoplasm	L & L Bio Co., Ltd., Ningbo, China	P1/2	CC (45)
leu011 Neoplasm	Leucid Bio	P1/2	CC (45)
Monoclonal Antibody Trk-950 Neoplasm	Toray Industries, Inc	P1/2	CC (45)
oh2 Neoplasm	Binhui Biopharmaceutical Co., Ltd.	P1/2	CC (45)
or502 Neoplasm	OncoResponse, Inc.	P1/2	CC (45)
qlc1101 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (45)
rd14-01 Neoplasm	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	P1/2	CC (45)
TIL Neoplasm	Fujian Cancer Hospital	P1/2	CC (45)
Triadeno Vaccine Neoplasm	National Cancer Institute (NCI)	P2	CC (45)
xnw29016 Neoplasm	Evopoint Biosciences Inc.	P1/2	CC (45)
Zovostotug Neoplasm	OncoResponse, Inc.	P1/2	CC (45)
68ga-nota-sna002 Neoplasm	SmartNuclide Biopharma	P1	CC (44)
Agent-797 Neoplasm	MiNK Therapeutics	P1	CC (44)
Cobolimab Neoplasm	GlaxoSmithKline	P1	CC (44)
Daratumumab Neoplasm	Hellenic Society of Hematology	P1/2	CC (44)
Disitamab Vedotin Neoplasm	RemeGen Co., Ltd.	P1	CC (44)
Enzalutamide Neoplasm	GlaxoSmithKline	P1	CC (44)
Fludeoxyglucose Neoplasm	Peking University Cancer Hospital & Institute	P1	CC (44)
Hmbd-002 Neoplasm	Hummingbird Bioscience	P1	CC (44)
lb4330 Neoplasm	L & L Bio Co., Ltd., Ningbo, China	P1/2	CC (44)
131i-ipa Neoplasm	Telix Pharmaceuticals (Innovations) Pty Limited	P1	CC (43)
177lu-nrt6020 Neoplasm	Chengdu New Radiomedicine Technology Co. LTD.	P1	CC (43)
Acetazolamide Neoplasm	M.D. Anderson Cancer Center	P1	CC (43)
Ati-2231 Neoplasm	Washington University School of Medicine	P1	CC (43)
azd6738 Neoplasm	AstraZeneca	P1	CC (43)

Showing 251 to 300 of 890 assets

PreviousPage 6 of 18Next